ArticlePharmacoEconomics1994
Cost-effectiveness opportunities for new antibiotics.
Article in PharmacoEconomics, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 11 citations in OpenAlex.
- An Evaluation of Antibiotic Prescribing Practices in a Rural Refugee Settlement District in Uganda.Antibiotics (Basel, Switzerland) · 2021Article
- An evaluation of prescribing practices for community-acquired pneumonia (CAP) in Mongolia.BMC health services research · 2013Article
- [A pharmacoeconomic study of the antibiotic treatment of the acute manifestations of chronic bronchitis in primary care. The DAFNE Group].Atencion primaria · 2000Article
- Article
- Costs, innovation and efficiency in anti-infective therapy.PharmacoEconomics · 1996Review
- Defining criteria for the pharmacoeconomic evaluation of new oral cephalosporins.PharmacoEconomics · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibacterial drugs account for between 6 and 21% of the drug market in various countries, or between 3 and 25% of the total prescriptions. Given the high usage of these agents, they are appropriate candidates for economic appraisal in the near future. It is probable that the marketplace and healthcare reform will give managed care the dominant position in the US healthcare system. Cost-effectiveness analyses of managed care organisations are based on both hospital and outpatient costs, and they are increasingly being aimed at formulary decisions regarding pharmaceuticals. Appropriate outcome parameters, long term follow-up, and phase IV trials to determine costs and outcomes relating to actual clinical use are needed to assess cost-effectiveness. Unbiased pharmacoeconomic research is needed to accurately answer questions on the economic viability of new products, and to avoid scepticism on the part of the purchasers of healthcare. The ultimate challenge for research and development of new antibiotics will be to reconcile the needs of the patient with the economic needs of society, within the cost-effectiveness paradigm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.